What is CODX's current stock price?

CODX (Co-Diagnostics, Inc.) is currently trading at $5.07 with a market cap of $5.7M.

What sector is Co-Diagnostics, Inc. in?

Co-Diagnostics, Inc. (CODX) operates in the Healthcare sector, specifically in the Medical - Devices industry.

Is CODX a good stock to buy?

Analysts have a Hold consensus on CODX with a price target of $180.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

CODX Co-Diagnostics, Inc.

Healthcare

$5.07+36.66%ClosedMarket Cap: $5.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.71

P/S

7.88

EV/EBITDA

0.02

DCF Value

$7.43

FCF Yield

-512.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

9.5%

Operating Margin

-4447.4%

Net Margin

-6753.7%

ROE

-164.9%

ROA

-225.6%

ROIC

-171.0%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$146.0K	$-9.1M	$—
Q4 null	$263.9K	$-25.7M	$—
FY null	$622.5K	$-46.9M	$—
Q3 null	$145.4K	$-5.9M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$180.00

Target (Median)

$180.00

Target Range

$180.00 - $180.00

0 Strong Buy0 Buy2 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Neutral

2025-11-24

D. Boral CapitalBuy

2025-10-28

D. Boral CapitalBuy

2025-09-19

D. Boral CapitalBuy

2025-08-15

Trading Activity

Insider Trades

View All

Murphy Edward L.director

SellMon Nov 24

Murphy Edward L.director

SellMon Nov 24

Egan Dwight Hdirector, officer: Chief Executive Officer

SellMon Nov 24

Egan Dwight Hdirector, officer: Chief Executive Officer

SellMon Nov 24

Brown Brian Leeofficer: Chief Financial Officer

SellMon Nov 24

Latest News

Co-Diagnostics Ships Diagnostic Materials to India for Initiation of Tuberculosis Clinical Studies Following Recently Issued Guidance from the World Health OrganizationPRNewsWire · Wed Mar 25

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

Exchange

—

Beta

1.26

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.

Peers